Results 51 to 60 of about 192,309 (409)
No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke [PDF]
, 2012 Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Bohmann, Ferdinand +6 more
core +7 more sources
Pharmaceutics, 2022 Warfarin is extensively used for venous thromboembolism and other coagulopathies. In clinical settings, warfarin is administered as a mixture of S- and R-warfarin, and both enantiomers are metabolized by multiple cytochrome P450 enzymes into many ...
Shasha Jin +6 more
doaj +1 more source
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
New England Journal of Medicine, 2013 BACKGROUND Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous ...
H. Büller +12 more
semanticscholar +1 more source
Appropriateness of oral anticoagulants for long-term treatment of atrial fibrillation in older people: results of an evidence-based review and international consensus validation process (OAC-FORTA 2016) [PDF]
, 2017 Background: Age appropriateness of anticoagulants for stroke prevention in atrial fibrillation is uncertain. Objective: To review oral anticoagulants for the treatment of atrial fibrillation in older (age >65 years) people and to classify ...
Collins, Ronan +10 more
core +1 more source
Evaluating the Effect of Longitudinal Dose and INR Data on Maintenance Warfarin Dose Predictions [PDF]
arXiv, 2021 Warfarin, a commonly prescribed drug to prevent blood clots, has a highly variable individual response. Determining a maintenance warfarin dose that achieves a therapeutic blood clotting time, as measured by the international normalized ratio (INR), is crucial in preventing complications.
arxiv
Bleeding with direct oral anticoagulants vs warfarin: clinical experience. [PDF]
, 2016 The risk of bleeding in the setting of anticoagulant therapy continues to be re-evaluated following the introduction of a new generation of direct oral anticoagulants (DOACs).
Eikelboom, John, Merli, Geno J.
core +2 more sources
Spontaneous abdominal hemorrhage due to warfarin treatment
CHRISMED Journal of Health and Research, 2016 Warfarin is an anticoagulant used in the prevention of thromboembolism. Common clinical indications for warfarin use are atrial fibrillation, artificial heart valves, deep venous thrombosis. Common side effect of warfarin is hemorrhage.
Mustafa Volkan Demir +3 more
doaj +1 more source
JAMA Neurology, 2019 Key Points Question Is dabigatran etexilate or dose-adjusted warfarin efficacious and safe to use in preventing the recurrence of venous thrombotic events among patients with cerebral venous thrombosis? Findings In this exploratory randomized, open-label
J. Ferro +14 more
semanticscholar +1 more source
NOACs versus warfarin for stroke prevention in patients with AF : a systematic review and meta-analysis [PDF]
, 2016 Acknowledgments Revman software was used for meta-analysis, a free download from the Cochrane Collaboration. GRADE pro software was used to formulate the GRADE summary of findings table, a free download from the GRADE working group.Peer reviewedPublisher
Eisinga, Anne +2 more
core +1 more source
British medical journal, 2018 Objective To investigate the associations between direct oral anticoagulants (DOACs) and risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality compared with warfarin. Design Prospective open cohort study. Setting UK general
Y. Vinogradova +3 more
semanticscholar +1 more source